| ■ 영문 제목 : Acinetobacter Pneumonia Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Xacduro, Polymyxins, Cephalosporins, Carbapenems), By Route Of Administration (Oral, Parenteral), By Region, And Segment Forecasts, 2024 - 2030
|
 | ■ 상품코드 : GRV24MAY096
■ 조사/발행회사 : Grand View Research
■ 발행일 : 2024년 4월
■ 페이지수 : 150
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (3일 소요)
■ 조사대상 지역 : 세계
■ 산업 분야 : 의료/바이오
|
■ 판매가격 / 옵션
(부가세 10% 별도)
| Single User (1인 열람용) | USD5,950 ⇒환산￦8,032,500 | 견적의뢰/주문/질문 |
| Multi User (5인 열람용) | USD6,950 ⇒환산￦9,382,500 | 견적의뢰/주문/질문 |
| Global/corporate License (기업 열람용) | USD8,950 ⇒환산￦12,082,500 | 견적의뢰/구입/질문 |
※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
|
글로벌 아시네토박테르 폐렴 치료제 시장의 성장과 동향
Grand View Research, Inc.사의 최신 보고서에 따르면, 세계의 아시네토박테르 폐렴 치료제 시장 규모는 2024년부터 2030년까지 6. 70%의 CAGR을 기록하며 2030년까지 4억 7,096만 달러에 달할 것으로 예상됩니다. 시장 성장 요인으로는 아시네토박테르 감염의 높은 발생률, 항생제 내성 증가, 광범위한 연구 개발, 유리한 정부 이니셔티브 및 자금 지원, 약물 내성 증가 등이 있습니다. 아시네토박테르 바우만니는 입원 환자의 병원 내 감염을 일으키는 주요 병원균입니다. 이 병원균은 인공호흡기 관련 폐렴과 혈류 감염을 유발합니다. 이 균주는 다제 내성이 있는 것으로 보고되고 있으며, 매우 빠르게 확산됩니다.
이 미생물의 치료는 어렵고, 아시네토박테르 바우마니의 다제내성으로 인해 치료가 어렵습니다. 병용 요법은 이러한 유형의 감염을 치료하는 데 가장 널리 사용되는 치료법입니다. 아시네토박테르 폐렴 치료의 1차 선택 약물은 β-락탐계 항생제, 세팔로스포린계 항생제, 카바페넴계 항생제, 플루오로퀴놀론계 항생제, 설박탐계 항생제, 설폰아미드계 항생제 등입니다. 이들 치료제는 중증도에 따라 단독 또는 병용 요법의 일부로 사용됩니다. 1차 선택 약물이 효과가 없을 경우, 아미노글리코사이드계, 폴리믹신계, 테트라사이클린계, 글리실사이클린계 등의 항생제를 2차 선택 약물로 투여합니다. 이들 약제는 부작용 때문에 2차 선택 약물로 분류됩니다.
아시네토박테르 폐렴 치료제 시장 보고서 주요 내용
- 세팔로스포린 계열은 2023년 가장 큰 매출 점유율을 차지했습니다. 세프타디짐은 1차 선택 약물로, 세피데로콜은 2차 선택 약물로 사용됩니다.
- 또한, 설박탐 계열의 경우, 새로 출시된 자쿠듀로가 예측 기간 동안 높은 CAGR로 성장할 것으로 예상됩니다.
- 투여 경로별로는 비경구 투여 부문이 2023년 가장 큰 매출 점유율을 차지할 것으로 예상됩니다. 정맥 투여를 통한 항생제의 신속하고 직접적인 전달은 빠른 흡수와 효능을 보장하여 심각한 감염을 치료하는 데 선호되는 방법입니다.
- 자쿠듀로(주사용 설박탐, 주사용 듀로박탐), 폴리믹신(콜리스틴), 카바페넴계 항생제, 아미노글리코사이드계 항생제 등이 아세트박터 폐렴 치료에 사용되는 비경구용 항생제 중 일부입니다.
- 2023년 북미는 첨단 의료 인프라, 높은 인지도, 임상 시험을 위한 광범위한 연구 활동으로 인해 37. 31%의 점유율을 차지했습니다.
- 이 지역은 아시네토박테르 폐렴의 유병률이 높고, 질병 진단 및 치료에 대한 인식이 높은 지역입니다. |
■ 보고서 개요1. 조사 방법 및 범위
2. 개요
3. 시장 변수, 동향 및 범위
4. 세계의 아시네토박테르 폐렴 치료제 시장 약물 종류별 예측 및 동향 분석
5. 세계의 아시네토박테르 폐렴 치료제 시장 투여 경로별 예측 및 동향 분석
6. 세계의 아시네토박테르 폐렴 치료제 시장 지역별 예측 및 동향 분석
7. 경쟁 현황
■ 보고서 목차Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Route of Administration
1.3. Regional scope
1.4. Estimates and forecasts timeline
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased database
1.6.2. GVR’s internal database
1.6.3. Secondary sources
1.6.4. Primary research
1.6.5. Details of primary research
1.6.5.1. Data for primary interviews in North America
1.6.5.2. Data for primary interviews in Europe
1.6.5.3. Data for primary interviews in Asia Pacific
1.6.5.4. Data for primary interviews in Latin America
1.6.5.5. Data for Primary interviews in MEA
1.7. Information or Data Analysis
1.7.1. Data analysis models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity flow analysis (Model 1)
1.9.2. Approach 1: Commodity flow approach
1.9.3. Volume price analysis (Model 2)
1.9.4. Approach 2: Volume price analysis
1.10. List of Secondary Sources
1.11. List of Primary Sources
1.12. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug class outlook
2.2.2. Route of administration outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Acinetobacter Pneumonia Therapeutics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing incidence of Acinetobacter infections
3.2.1.2. Increasing prevalence of antibiotic resistance
3.2.1.3. Increasing research & development and fundings
3.2.2. Market restraint analysis
3.2.2.1. Side effects and adverse reactions
3.2.2.2. High cost of drug development
3.3. Acinetobacter Pneumonia Therapeutics Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pricing Analysis
3.3.4. Pipeline Analysis
Chapter 4. Acinetobacter Pneumonia Therapeutics Market: Drug Class Estimates & Trend Analysis
4.1. Global Acinetobacter Pneumonia Therapeutics Market: Drug Class Segment Dashboard
4.2. Global Acinetobacter Pneumonia Therapeutics Market: Drug Class Movement Analysis
4.3. Global Acinetobacter Pneumonia Therapeutics Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
4.4. Cephalosporins
4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Fluoroquinolone
4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Glycylcycline
4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Carbapenem
4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.8. β-Lactam antibiotics
4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Sulbactam
4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.10. Aminoglycoside
4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.11. Polymyxins
4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.12. Tetracycline
4.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.13. Sulfonamide
4.13.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.14. Other
4.14.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Acinetobacter Pneumonia Therapeutics Market: Route of Administration Estimates & Trend Analysis
5.1. Global Acinetobacter Pneumonia Therapeutics Market: Route of Administration Segment Dashboard
5.2. Global Acinetobacter Pneumonia Therapeutics Market: Route of Administration Movement Analysis
5.3. Global Acinetobacter Pneumonia Therapeutics Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
5.4. Parenteral
5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Oral
5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Other
5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Acinetobacter Pneumonia Therapeutics Market: Regional Estimates & Trend Analysis by
6.1. Regional Market Dashboard
6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.3. North America
6.3.1. U.S.
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework/ reimbursement structure
6.3.1.3. Competitive scenario
6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.3.2. Canada
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework/ reimbursement structure
6.3.2.3. Competitive scenario
6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework/ reimbursement structure
6.4.1.3. Competitive scenario
6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Germany
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework/ reimbursement structure
6.4.2.3. Competitive scenario
6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. France
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework/ reimbursement structure
6.4.3.3. Competitive scenario
6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4. Italy
6.4.4.1. Key country dynamics
6.4.4.2. Regulatory framework/ reimbursement structure
6.4.4.3. Competitive scenario
6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.4.5. Spain
6.4.5.1. Key country dynamics
6.4.5.2. Regulatory framework/ reimbursement structure
6.4.5.3. Competitive scenario
6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.4.6. Norway
6.4.6.1. Key country dynamics
6.4.6.2. Regulatory framework/ reimbursement structure
6.4.6.3. Competitive scenario
6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.4.7. Sweden
6.4.7.1. Key country dynamics
6.4.7.2. Regulatory framework/ reimbursement structure
6.4.7.3. Competitive scenario
6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.4.8. Denmark
6.4.8.1. Key country dynamics
6.4.8.2. Regulatory framework/ reimbursement structure
6.4.8.3. Competitive scenario
6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.5.2. China
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.5.3. India
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/ reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.5.4. Australia
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/ reimbursement structure
6.5.4.3. Competitive scenario
6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.5.5. South Korea
6.5.5.1. Key country dynamics
6.5.5.2. Regulatory framework/ reimbursement structure
6.5.5.3. Competitive scenario
6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.5.6. Thailand
6.5.6.1. Key country dynamics
6.5.6.2. Regulatory framework/ reimbursement structure
6.5.6.3. Competitive scenario
6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.6.2. Mexico
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
6.6.3. Argentina
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework/ reimbursement structure
6.6.3.3. Competitive scenario
6.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.7.2. Saudi Arabia
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.7.3. UAE
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/ reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.7.4. Kuwait
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/ reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2023
7.3.4. Pfizer Inc.
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Merck & Co., Inc.
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. GlaxoSmithKline plc (GSK)
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. AstraZeneca plc
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Novartis AG
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Johnson & Johnson
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Sanofi S.A.
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. Bayer AG
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Product benchmarking
7.3.11.4. Strategic initiatives
7.3.12. Basilea Pharmaceutica
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Product benchmarking
7.3.12.4. Strategic initiatives
|
| ※본 조사보고서 [세계의 아시네토박테르 폐렴 치료제 시장 2024-2030 : 자쿠듀로, 폴리믹신, 세팔로스포린, 카바페넴] (코드 : GRV24MAY096) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [세계의 아시네토박테르 폐렴 치료제 시장 2024-2030 : 자쿠듀로, 폴리믹신, 세팔로스포린, 카바페넴] 에 대해서 E메일 문의는 여기를 클릭하세요. |
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!
